Leucocyte interferon-alpha for patients with chronic hepatitis C intolerant to other alpha-interferons

BioDrugs

Volumn 17, Issue 3, 2003, Pages 201-205

  Tripi, Silvio ^a   Soresi, Maurizio ^a   Di Gaetano, Giuseppa ^a   Carroccio, Antonio ^a   Giannitrapani, Lydia ^a   Vuturo, Onofrio ^a   Di Giovanni, Gaetana ^a   Montalto, Giuseppe ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Cattedra di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA INTERFERON A; FLUOXETINE; INSULIN; LYMPHOBLAST INTERFERON; MICROSOME ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HASHIMOTO DISEASE; HEART ATRIUM FIBRILLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTHERMIA; HYPOTHYROIDISM; INTERVIEW; LABORATORY TEST; LEUKOPENIA; LIBIDO DISORDER; LIVER BIOPSY; LIVER FUNCTION; MALE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 0038621335     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317030-00006     Document Type: Article

References (22)

1. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
2. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92
4. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon-alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-9
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426-32
6. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon-alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65
8. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47
9. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-91
10. Montalto G, Soresi M, Carroccio A, et al. Comparative responses to three different types of interferon-alpha in patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 235-41
11. Cacopardo B, Benanti F, Brancati G, et al. Leukocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat 1998; 5: 333-9
12. Gaeta GB, Di Virgilio D, Russo G, et al. Human leukocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomised controlled trial. J Viral Hepat 1997; 4: 209-14
13. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, staging. Hepatology 1994; 19: 1513-20
14. Giannini C, Thiers V, Nousbaum JB, et al. Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers of probes. J Hepatol 1995; 23: 146-53
15. Colombatto P, Oliveri F, Leandro G, et al. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Ital J Gastroenterol Hepatol 1997; 29: 441-7
16. Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748-52
17. Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-7
18. Cagnoni C, Pancotti D, Carrara G. Management of patients with HCV infection poorly tolerant to recombinant Interferon alpha. Hepatogastroenterology 2000; 47: 199-203
19. Gattoni A, Romano C, Cecere A, et al. Efficacy of human leukocyte interferon treatment in elderly patients with hepatitis C virus-related chronic liver disease. Arch Gerontol Geriatr 1996; 22-23 Suppl. 5: 305-12
20. Dughera L, Battaglia E, Serra AM, et al. Human leukocyte interferon-alpha treatment for chronic HCV-related hepatitis in hemophilic patients previously intolerant to other interferons-alpha. Dig Dis Sci 2002; 47: 427-31
21. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20: 374-80
22. Custro N, Carroccio A, Ganci A, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001; 27: 476-81